Nicoletta Brega

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Walter Fiedler, Hubert Serve, Hartmut Döhner et al. · Blood · 2005 · 492 citations

Medicine, Oncology, Pharmacology +13

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Walter Fiedler, Rolf M. Mesters, Heike Tinnefeld et al. · Blood · 2003 · 263 citations · Full text

Medicine, Hematology, Oncology +8

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel et al. · Clinical Cancer Research · 2011 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Steven G. Waguespack, Alexander Drilon, Marcia S. Brose et al. · The Medicine Forum · 2022 · 125 citations · Full text

Medicine, Oncology, Pharmacology +15